A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban

@inproceedings{Frost2014ARD,
  title={A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban},
  author={Charles E. Frost and Yan Song and Yu Chen Barrett and Jessie Yi-jia Wang and Janice M Pursley and Rebecca A. Boyd and Frank P Lacreta},
  booktitle={Clinical pharmacology : advances and applications},
  year={2014}
}
BACKGROUND Currently, there are no direct comparisons of apixaban and rivaroxaban, two new oral direct factor Xa inhibitors approved for management of thromboembolic disorders. OBJECTIVE Compare the pharmacokinetics and anti-factor Xa activity (AXA) of apixaban and rivaroxaban. METHODS In this randomized, open-label, two-period, two-treatment crossover study, healthy subjects (N=14) received apixaban 2.5 mg twice daily (BID) and rivaroxaban 10 mg once daily (QD) for 4 days with a ≥4.5-day… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS